ORYN 1001
Alternative Names: ORTD; ORTD-1; ORYN-1001Latest Information Update: 28 Dec 2023
At a glance
- Originator Oryn Therapeutics
- Class Antimicrobial cationic peptides; Antirheumatics; Macrocyclic compounds; Peptides
- Mechanism of Action Immunomodulators; NF-kappa B inhibitors; Tumour necrosis factor-alpha convertase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in USA (SC, Injection)
- 12 Oct 2021 Oryn Therapeutics completes a phase I trial in Rheumatoid arthritis in USA (NCT04286789)
- 14 Jun 2021 Oryn Therapeutics withdraws recruitment in phase I/II trial in COVID-19 pneumonia in USA (IV) (NCT04708236)